Generic Drug Approvals Bromfenac
February 2, 2024FDA Approves Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
February 12, 2024Deflazacort – Approved February 9, 2024
Brand name: Emflaza
Dosage forms: oral suspension (22.75 mg/mL), oral tablet (18 mg; 30 mg; 36 mg; 6 mg)
Drug class: Glucocorticoids
Deflazacort is a steroid that is used to treat Duchenne muscular dystrophy in adults and children at least 2 years old.
Deflazacort is not a cure for muscular dystrophy, but deflazacort may improve muscle strength and slow the progression of disability.